Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acetaminophen OD Deaths Unintentional 22% Of The Time, FDA Analysis Says

This article was originally published in The Tan Sheet

Executive Summary

Unintentional misuse of acetaminophen causes fewer than one-quarter of annual overdose deaths involving the analgesic, FDA says in briefing documents for the Nonprescription Drugs Advisory Committee meeting on analgesic safety Sept. 19-20

You may also be interested in...



Naproxen Directly Linked To GI Bleeding In 32% Of Cases Reviewed By FDA

Nearly one-third of gastrointestinal hemorrhage cases related to OTC naproxen sodium use did not involve additional risk factors, FDA reports in a recently released postmarketing safety review

Naproxen Directly Linked To GI Bleeding In 32% Of Cases Reviewed By FDA

Nearly one-third of gastrointestinal hemorrhage cases related to OTC naproxen sodium use did not involve additional risk factors, FDA reports in a recently released postmarketing safety review

Naproxen Directly Linked To GI Bleeding In 32% Of Cases Reviewed By FDA

Nearly one-third of gastrointestinal hemorrhage cases related to OTC naproxen sodium use did not involve additional risk factors, FDA reports in a recently released postmarketing safety review

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel